Compare ATS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | LQDA |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2007 | 2020 |
| Metric | ATS | LQDA |
|---|---|---|
| Price | $28.47 | $37.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $35.00 | ★ $41.00 |
| AVG Volume (30 Days) | 158.8K | ★ 1.2M |
| Earning Date | 02-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $17.99 | $265.61 |
| Revenue Next Year | $3.91 | $62.82 |
| P/E Ratio | $222.92 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $20.90 | $11.26 |
| 52 Week High | $33.01 | $46.67 |
| Indicator | ATS | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 55.12 |
| Support Level | $26.62 | $31.75 |
| Resistance Level | $30.52 | $39.19 |
| Average True Range (ATR) | 1.25 | 1.80 |
| MACD | -0.19 | 0.20 |
| Stochastic Oscillator | 28.57 | 77.42 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.